Zist Daru Danesh

Zist Daru Danesh is a prominent Iranian biotechnology company dedicated to the production of high-tech medicines, particularly for the treatment of Multiple Sclerosis. Established in 2005, the company has developed a robust portfolio that includes biosimilars and complex generics such as interferon beta-1b and fingolimod. Their operations encompass the entire value chain from research and development to large-scale GMP manufacturing. By focusing on high-cost specialty drugs, Zist Daru Danesh plays a critical role in the Iranian healthcare system by improving patient access to essential therapies. The company continues to expand its reach into oncology and other therapeutic areas through innovative pharmaceutical solutions.